The University Hospitals of Leicester (UHL) NHS Trust, with just under 2000 beds is one of the biggest and busiest trusts in the country, serving the one million residents of Leicester, Leicestershire and Rutland. Our nationally and internationally-renowned specialist treatment and services in cardio-respiratory diseases, ECMO, cancer and renal disorders reach a further two to three million patients from the rest of the country.
Leicester has an Experimental Cancer Medicine Centre and their HOPE Clinical Trials Facility is an instrumental factor in delivering clinical trials of new cancer treatments, which is generously supported by the locally-based charity Hope Against Cancer.
The heart centre at the Glenfield hospital continues to lead the way in developing new and innovative research and techniques, such as TAVI (Trans-Catheter Aortic Valve Insertion) and the use of the sutureless valves in heart surgery. It has also become one of the world’s busiest ECMO (extracorporeal membrane oxygenation) centres and the only hospital in the UK to provide ECMO therapy for both adults and children.
The University of Leicester is a leading university committed to international excellence, world-changing research and high quality, inspirational teaching. They are proud to be one of the world's leading research-intensive universities, elite in the excellence of their research.
The NIHR Leicester BRC is at the frontier of research into illnesses linked to respiratory conditions, cardiovascular disease, Type 2 diabetes, chronic kidney disease and the consequences of inactivity. Their overall purpose is to translate scientific breakthroughs in these areas into diagnostic tests, preventions and life-saving treatments for their patients.
UHL are one of the biggest and busiest NHS trusts in the country, serving the one million residents of Leicester, Leicestershire and Rutland - and increasingly specialist services over a much wider area. They are committed to research and development in order to improve patient care and at any one time there are more than 800 research projects active in the Trust.
ARC East Midlands is a collaboration made up of world class clinical academics, NHS and other health and social care partners supported by close relations with the public. Its primary aim is to deliver a program of research aimed at improving outcomes for patients and the public and to increase the efficiency, quality, accessibility and sustainability of care services. All of our research will be of the highest scientific quality and addresses the most important health and care challenges for communities across our region and nationally.
The National Centre for Sport and Exercise Medicine (NCSEM) is an Olympic legacy project delivering education, research and clinical services in sport, exercise and physical activity. It aims to apply world-class expertise to policies and practice that will benefit the health and wellbeing of the nation – from everyday people at risk of ill health through to elite athletes.
The Clinical Research Facilities (CRF) mission is to support excellent early translational studies in order to increase understanding of disease, evaluate new treatments and improve the health of our patients.Leicester CRF provides the people, expertise, space and equipment to conduct world-class experimental medicine research and early phase clinical trials. Our facilities are integrated into clinical areas within specialities to provide a seamless link from the laboratory bench to bedside.
Academic Health Science Networks have a primary responsibility to their member and partner organisations within the geography in which they operate. Each of the 15 AHSNs has developed a bespoke offer that reflects local priorities, whilst contributing to the collective AHSN endeavour. EMAHSN’s focus is on delivering outcomes more efficiently through the adoption and spread of proven innovations and initiatives at pace and scale.
Leicester ECMC has expertise in developing novel therapeutic strategies to treat cancer, particularly lung cancer and haematological malignancies.
A cornerstone of the Centre’s research is to discover and develop novel phytochemicals as potential cancer chemopreventive agents and/or as potential adjuncts to chemotherapy. Biomarker studies aim to inform treatment decisions and monitor the effectiveness of therapies.